T-Cell Non-Hodgkin Lymphoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

CD5 Expression
CD7 Expression
Complex karyotype
EBV Positive
Loss of Y
MS4A1 Expression
Monosomy 7
Normal karyotype
TNFRSF8 Deficient Expression
TNFRSF8 Expression
TRBC1 Expression
Very Complex karyotype
del(20)(q10)
del(5)(q10)
del(7)(q10)

Overview

T-cell non-hodgkin lymphomas most frequently harbor alterations in TET2, DNMT3A, RHOA, TP53, and KMT2D [2].

Most Commonly Altered Genes in T-Cell Non-Hodgkin Lymphoma

TET2 Mutation, TET2fs, RHOA Mutation, TET2 Nonsense, and RHOA G17V are the most common alterations in T-cell non-hodgkin lymphoma [2].

Top Alterations in T-Cell Non-Hodgkin Lymphoma

Clinical Trials

View Clinical Trials for T-Cell Non-Hodgkin Lymphoma

There are 24 clinical trials for T-cell non-hodgkin lymphoma, of which 21 are open and 3 are completed or closed. Of the trials that contain T-cell non-hodgkin lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 8 are phase 1 (7 open), 5 are phase 1/phase 2 (5 open), 9 are phase 2 (7 open), and 1 is no phase specified (1 open).

CD7, MS4A1, and CD5 are the most frequent gene inclusion criteria for T-cell non-hodgkin lymphoma clinical trials [3].

Trials Investigating T-Cell Non-Hodgkin Lymphoma by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most common interventions in T-cell non-hodgkin lymphoma clinical trials.

Drugs Being Investigated in T-Cell Non-Hodgkin Lymphoma Trials by Recruiting Status

Significant Genes in T-Cell Non-Hodgkin Lymphoma

ABL1 +

ABL1 is altered in 0.87% of T-cell non-hodgkin lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ASXL1 +

ASXL1 is altered in 2.91% of T-cell non-hodgkin lymphoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR +

BCR is altered in 1.32% of T-cell non-hodgkin lymphoma patients [2].

BCR is an inclusion eligibility criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR status and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DEK status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ELL status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 +

FLT3 is altered in 2.03% of T-cell non-hodgkin lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A +

KMT2A is altered in 3.2% of T-cell non-hodgkin lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM +

MECOM is altered in 5.6% of T-cell non-hodgkin lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 +

NPM1 is altered in 1.17% of T-cell non-hodgkin lymphoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP214 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 2 clinical trials for T-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RPN1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RUNX1 +

RUNX1 is altered in 1.17% of T-cell non-hodgkin lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 +

TP53 is altered in 12.43% of T-cell non-hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

Lymph node lymphoma T-cell (NOS)

Parent(s)

Non-Hodgkin Lymphoma

Children

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma and T-Cell Lymphoblastic Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.